Supplementary Figure S5 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Average TLS signature expression differs significantly between responders and non-responders to treatment.
Responders showed TLS expression less than or equal to ypT1N0, while non-responders exhibited ypT2-4aNx or ypTxN1-3.
Analysis utilized bulk RNA sequencing samples to establish expression profiles for both response groups.
Findings suggest that the TLS signature may help predict treatment outcomes in urothelial cancer patients.

Answers are grounded in this paper and cite their sources.

Analysis shows TLS signature differences in responders and non-responders to ipilimumab and nivolumab treatment.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Stockem et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share